{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"The number of patients who had a DLT during the dose finding portion (Phase I) of the trial for the safety of lenalidomide when used in combination with high dose melphalan in the setting of autologous stem cell transplantation in patients with multiple myeloma.","groups":[{"description":"All patients will receive Melphalan 100 mg/m2 intravenously day -2 and day -1 and Lenalidomide 50 mg given daily day -7 to day +2","id":"OG000","title":"Phase I, Dose Level 1"},{"description":"All patients will receive Melphalan 100 mg/m2 intravenously day -2 and day -1 and Lenalidomide 75 mg given daily day -7 to day +2","id":"OG001","title":"Phase I, Dose Level 2"},{"description":"All patients will receive Melphalan 100 mg/m2 intravenously day -2 and day -1 and Lenalidomide 100 mg given daily day -7 to day +2","id":"OG002","title":"Phase I, Dose Level 3"},{"description":"All patients will receive Melphalan 100 mg/m2 intravenously day -2 and day -1 and Lenalidomide 150 mg given daily day -7 to day +2","id":"OG003","title":"Phase I, Dose Level 4"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Phase I patients receiving at least one dose of study drug and having at least one evaluable post-baseline visit (16 patients)","reportingStatus":"POSTED","timeFrame":"up to 1 month","title":"Phase I: Number of Patients With Dose Limiting Toxicity","type":"PRIMARY","unitOfMeasure":"Participants"}